TransCode Therapeutics Statistics Share Statistics TransCode Therapeutics has 833.68K
shares outstanding. The number of shares has increased by -0.79%
in one year.
Shares Outstanding 833.68K Shares Change (YoY) -0.79% Shares Change (QoQ) -0.78% Owned by Institutions (%) 0.09% Shares Floating 833.68K Failed to Deliver (FTD) Shares 257 FTD / Avg. Volume 0.22%
Short Selling Information The latest short interest is 54.46K, so 6.53% of the outstanding
shares have been sold short.
Short Interest 54.46K Short % of Shares Out 6.53% Short % of Float 6.53% Short Ratio (days to cover) 2.25
Valuation Ratios The PE ratio is -1.4 and the forward
PE ratio is -1.15.
TransCode Therapeutics's PEG ratio is
0.01.
PE Ratio -1.4 Forward PE -1.15 PS Ratio 0 Forward PS 17.8 PB Ratio -11.66 P/FCF Ratio -1.76 PEG Ratio 0.01
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for TransCode Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.56,
with a Debt / Equity ratio of -0.02.
Current Ratio 2.56 Quick Ratio 2.56 Debt / Equity -0.02 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage -584.07
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-2.39M Employee Count 7 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -93.74% in the
last 52 weeks. The beta is 1.48, so TransCode Therapeutics's
price volatility has been higher than the market average.
Beta 1.48 52-Week Price Change -93.74% 50-Day Moving Average 8.9 200-Day Moving Average 86.61 Relative Strength Index (RSI) 50.21 Average Volume (20 Days) 118,335
Income Statement
Revenue n/a Gross Profit n/a Operating Income -15.66M Net Income -16.75M EBITDA -16.19M EBIT -14.57M Earnings Per Share (EPS) -47.14
Full Income Statement Balance Sheet The company has 5.81M in cash and 38.29K in
debt, giving a net cash position of 5.77M.
Cash & Cash Equivalents 5.81M Total Debt 38.29K Net Cash 5.77M Retained Earnings -63.2M Total Assets 13.19M Working Capital 10.53M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -13.34M
and capital expenditures -21.76K, giving a free cash flow of -13.36M.
Operating Cash Flow -13.34M Capital Expenditures -21.76K Free Cash Flow -13.36M FCF Per Share -37.51
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields RNAZ does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for RNAZ is $280,
which is 2519.3% higher than the current price. The consensus rating is "Buy".
Price Target $280 Price Target Difference 2519.3% Analyst Consensus Buy Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on May 15, 2025. It was a
backward
split with a ratio of 1:28.
Last Split Date May 15, 2025 Split Type backward Split Ratio 1:28
Scores Altman Z-Score -11.62 Piotroski F-Score 2
